0:02
Hello, my name is Elena Jurns and I'm reporting from ACR 2026 in Orlando, Florida.
0:08
I will say that as a focused rheumatologist, I'm a little disappointed with the lack of ILD-specific scientific sessions this year.
0:17
Although the ones that I have been to have been excellent, and I was pleased that there were several posters on IPAF.
0:23
IPAF, if you remember, is interstitial pneumonia with autoimmune features.
0:28
It is characterized by ILD and autoimmune features such as Raynaud's, inflammatory arthritis, positive serologies, etc., etc. We can talk about this another time about the definition of IPAF.
0:41
But it is largely still a research classification, and as a result there are not a ton of studies on it, and definitely no population-based studies.
0:49
Most studies of IPAF are limited to tertiary referral centers and retrospective cohort studies.
0:56
IPAF is very hard to understand and characterize, and there is much unknown regarding its natural course, prognosis, etiology, and optimal treatment.
1:04
There are thoughts that IPAF may be a glorified idiopathic pulmonary fibrosis with positive antibodies, especially for those subtypes with usual interstitial pneumonia pattern.
1:13
Others wonder whether this is a systemic autoimmune rheumatic disease, or SARD, confined to the lung, and then maybe yet another subtype may simply be an early SARD that is in the lung and will eventually develop into a defined SARD.
1:28
And this is an important question, because if it is something like an early SARD, should we be immunosuppressing these people to prevent it?
1:36
Should we assume that these people have that SARD even before they get it?
1:40
Well, a few researchers from Texas Tech mostly decided to do just that — to figure out if IPAF progresses to SARD, and if so, which kinds of IPAF progress into which diseases.
1:51
Poster number 0683 by Dr. Chelersuk looked at the likelihood of progression from IPAF to SARD via systematic review and meta-analysis.
2:01
They found eight studies that looked at that question.
2:05
In those studies, presence of IPAF within cohorts of interstitial pneumonia was associated with seven times higher odds of progression to a SARD, most commonly scleroderma and rheumatoid arthritis.
2:17
They did not unfortunately present any conclusions regarding the timing of that progression.
2:22
Then poster number 1630 by Dr. Sodri, also from Texas Tech, looked at predictors of that progression in a meta-analysis.
2:30
They included four studies this time from the eight included in the project by Dr. Chelersuk.
2:37
They found that those who progressed to SARD were younger, and the presence of SCL antibody, mechanic's hands, and organizing pneumonia were predictors of progression to SARD in IPAF.
2:50
To me, those last two characteristics sound like some sort of myositis subtype.
2:55
Since most of the studies they included were retrospective, it is hard to know whether all those patients had a full set of anti-myositis antibodies checked.
3:03
These studies were much needed. The natural course of IPAF is poorly understood, and I think their systematic review emphasizes that there is still a gap in how we design studies in IPAF.
3:15
There are a lot more studies than eight in IPAF, and the fact that only eight studies looked at progression to SARD tells me that we're not looking at that question specifically.
3:27
We need more prospective studies so that we can definitively track who develops SARD and when.
3:32
And we need to make sure that any patient that we're evaluating with ILD gets deep phenotyping, and that includes a wide range of antibodies, so that we later can know better and understand which features truly predict that SARD development and progression. Thank you.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.